|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-6-13
|
|
pubmed:abstractText |
The present study was undertaken to estimate the therapeutic benefit to down-regulate the Na(+)/H(+) exchanger 1 (NHE1) for reversing chemoresistance of BCR-ABL-positive leukemia patient cells and cell lines. As a result, after treatment with specific NHE1 inhibitor Cariporide or high K(+) buffer to decrease intracellular pH (pH(i)), cells from relapsed patients exhibited decreased Pgp level, enhanced Rhodamine123 and drug accumulation, decreased colony-forming ability and the modulations of mitogen-activated protein kinases (MAPKs) activities. Furthermore, we used BCR-ABL-positive cell line K562 and its resistant counterparts K562/DOX and K562/G01 cell lines for further study. Together, these findings suggest that Pgp may be associated with the reversal of drug resistance in BCR-ABL-positive leukemia patients and cell lines by the inhibition of NHE1 though MAPK pathways.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1872-7980
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
308
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
81-90
|
|
pubmed:meshHeading |
pubmed-meshheading:21576001-Adolescent,
pubmed-meshheading:21576001-Adult,
pubmed-meshheading:21576001-Aged,
pubmed-meshheading:21576001-Cell Line, Tumor,
pubmed-meshheading:21576001-Child,
pubmed-meshheading:21576001-Child, Preschool,
pubmed-meshheading:21576001-Doxorubicin,
pubmed-meshheading:21576001-Drug Resistance, Neoplasm,
pubmed-meshheading:21576001-Drug Synergism,
pubmed-meshheading:21576001-Female,
pubmed-meshheading:21576001-Guanidines,
pubmed-meshheading:21576001-Humans,
pubmed-meshheading:21576001-K562 Cells,
pubmed-meshheading:21576001-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:21576001-Male,
pubmed-meshheading:21576001-Middle Aged,
pubmed-meshheading:21576001-Mitogen-Activated Protein Kinases,
pubmed-meshheading:21576001-Piperazines,
pubmed-meshheading:21576001-Pyrimidines,
pubmed-meshheading:21576001-Sodium-Hydrogen Antiporter,
pubmed-meshheading:21576001-Sulfones,
pubmed-meshheading:21576001-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger.
|
|
pubmed:affiliation |
State Key Laboratory of Experimental Hematology, Institute of Hematology, Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
